Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
Clin Lymphoma Myeloma Leuk
© 2020 Elsevier Inc. Ibrutinib-associated arthralgias/myalgias are a frequent adverse event that can occur late in the treatment course and are mostly grade 1 or 2. For patients with grade 1 or 2 arthralgias/myalgias, dose reductions can frequently mitigate the side effects and allow patients to continue on therapy, whereas the majority of patients with grade 3 toxicity ultimately discontinue therapy. Further study is needed to determine their pathogenesis in order to develop best practice management strategies.
School of Medicine